The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function

Clinical Nephrology

Volumn 71, Issue 2, 2009, Pages 118-124

  Aakre, Kristin Moberg ^a   Tondel C ^a,b   Brun, A ^a,b   Svarstad, E ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Chronic kidney disease; Cockcroft Gault equation; Fabry disease; Iohexol clearance; MDRD equation; Validation of estimated GFR

Indexed keywords

ALBUMIN; ALPHA GALACTOSIDASE; CREATININE; IOHEXOL;

ADULT; ALBUMINURIA; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COCKCROFT GAULT EQUATION; CONTROLLED STUDY; COUNAHAN BARRATT EQUATION; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTERMETHOD COMPARISON; KIDNEY FUNCTION; MALE; MATHEMATICAL COMPUTING; MDRD EQUATION; SEX DIFFERENCE; ADOLESCENT; CASE CONTROL STUDY; DISEASE COURSE; KIDNEY FAILURE; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; LINEAR MODELS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 64549128778     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71118     Document Type: Article

References (26)

1. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007; 146: 77-86.
2. Barbey F, Lidove O, Schwarting A. Fabry nephropathy: 5 years of enzyme replacement therapy - a short review. NDT Plus. 2008; 1: 11-19.
3. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol. 2003; 13 (Suppl 2): S139-S143.
4. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006; 69: 1216-1221.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
6. Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child. 1976; 51: 875-878.
7. Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr. 2004; 144 (Suppl): S20-S26.
8. Desnick R, Ioannou Y, Eng C. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic and molecular basis of inherited disease. New York: McGraw Hill; 2001, 3733-3774.
9. Eng CM, Guffon N, Wilcox WR Germain DP, Lee P, Waldeck S, Caplan L, Lindhorst GE, Desnick RJ. International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med. 2001; 345: 9-16.
10. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007; 18: 1547-1557.
11. GFR calculator. National Kidney Foundation. http://www.kidney.org/professionals/KDOQI/gfr.cfm. Accessed June 15, 2008.
12. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int. 1978; 13: 223-235.
13. Jacobsson L. Amethod for the calculation of renal clearance based on a single plasma sample. Clin Physiol. 1983; 3: 297-305.
14. Kleinert J, Lorenz M, Hauser AC, Becherer A, Staudenherz A, Fodinger M, Sunder-Plassmann G. Measurement of renal function in patients with Fabry disease. Acta Paediatr. 2005; 94 (Suppl): 19-23.
15. Lacomis D, Roeske-Anderson L, Mathie L. Neuropathy and Fabry's disease. Muscle Nerve. 2005; 31: 102-107.
16. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006; 21: 345-354.
17. Schiffmann R, Askar H, Timmons M, Robinson C, Benko W, Brady RO, Ries M. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol. 2007; 18: 1576-1583.
18. Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol. 2006; 66: 77-84.
19. Sima AA, Robertson DM. Involvement of peripheral nerve and muscle in Fabry's disease. Histologic, ultrastructural, and morphometric studies. Arch Neurol. 1978; 35: 291-301.
20. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, Levey AS. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007a; 18: 2749-2757.
21. Stevens LA, Manzi J, Levey AS, Chen J, Deysher AE, Greene T, Poggio ED, Schmid CH, Steffes MW, Zhang YL, Van Lente F, Coresh J. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis. 2007b; 50: 21-35.
22. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol. 2007; 18: 2609-2617.
23. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002; 62: 1933-1946.
24. Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008; 51: 767-776.
25. Uchino M, Uyama E, Kawano H, Hokamaki J, Kugiyama K, Murakami Y, Yasue H, Ando M. A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier. Acta Neuropathol (Berl). 1995; 90: 334-338.
26. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004; 75: 65-74.